Home›Research›Compare›ARA-290 vs Teriparatide
Peptide ComparisonARA-290 vs Teriparatide
Both are Longevity & Cellular peptides.
ARA-290
Cibinetide
Half-life: ~2 min (IV); ~10–20 min (SC)
16 providers listed
Teriparatide
Forteo
Half-life: ~1 hour
3 providers listed
Teriparatide is FDA-approved, while ARA-290 is investigational — the clearest structural difference between them.
ARA-290
Evidence
Half-life
~2 min (IV); ~10–20 min (SC)
Teriparatide
Evidence
Half-life
~1 hour
| Your goal | Better option |
|---|---|
| Stronger clinical evidence | Teriparatide |
| Further along in FDA review | Teriparatide |
| Less frequent dosing (longer half-life) | Teriparatide |
| More provider options (16 vs 3) | ARA-290 |
Research summary only — not medical advice. Consult a qualified provider before making any decisions.
ARA-290
Teriparatide
ARA-290
Immunometabolic dysregulation drives selective executive cognitive dysfunction in male db/db mice.
Cibinetide (ARA 290) reduces small nerve fiber pathology in sarcoidosis patients
ARA 290, a non-hematopoietic erythropoietin analogue, improves metabolic control and neuropathic symptoms in…
Teriparatide
The impact of parathyroid hormone supplementation on dental implant osseointegration in osteoporotic subjects…
Pharmacological Management of Primary Osteoporosis or Low Bone Mass to Prevent Fractures in Adults: A Living…
Association between antiosteoporosis medications and risk of sacral fracture after lumbosacral fusion in adul…
Consensus on the Treatment of Midshaft Clavicular Fractures in Collegiate Football Players: A Delphi Approach…
+3 more
About ARA-290
Non-hematopoietic EPO analogue; activates innate repair receptor (IRR/EPOR/CD131 complex) without erythropoietic effects; promotes tissue repair and nerve healing
About Teriparatide
Recombinant PTH 1-34; when given intermittently, preferentially activates osteoblasts over osteoclasts; increases bone remodeling and net bone formation; stimulates IGF-1 in bone
Information below reflects published research data only — not medical advice. Consult a qualified provider before use.
ARA-290
No established clinical contraindications
Teriparatide
No established clinical contraindications
Under clinical review
Being verified by our medical team before we display monitoring guidance for this peptide.
ARA-290
Teriparatide
Not enough vendor pricing yet.
Where to source these peptides
ARA-290
16 listed
Browse directory →
Providers offeringTeriparatide
3 listed
Browse directory →
PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.
More Longevity & Cellular Comparisons
Browse all peptides →Educational research tools — not medical advice.
Cite this page
Data last updated July 22, 2026
Free to reference and republish with attribution to PeptideBase. Choose a format:
PeptideBase. (2026). ARA-290 vs Teriparatide — Per-mg Price Comparison. Retrieved July 22, 2026, from https://peptidebase.io/peptides/compare/ara-290/teriparatide